Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teratoma | 3 | 2019 | 8 | 1.880 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2018 | 176 | 1.790 |
Why?
|
| Mouth Neoplasms | 5 | 2018 | 70 | 1.140 |
Why?
|
| Hodgkin Disease | 2 | 2018 | 11 | 0.960 |
Why?
|
| Ovarian Neoplasms | 3 | 2017 | 303 | 0.950 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 73 | 0.940 |
Why?
|
| Textile Industry | 1 | 2022 | 2 | 0.870 |
Why?
|
| Dust | 1 | 2022 | 51 | 0.820 |
Why?
|
| Occupational Exposure | 1 | 2022 | 67 | 0.810 |
Why?
|
| Skin | 3 | 2017 | 173 | 0.770 |
Why?
|
| Domestic Violence | 1 | 2020 | 24 | 0.770 |
Why?
|
| Neurilemmoma | 1 | 2019 | 3 | 0.720 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 17 | 0.710 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2019 | 9 | 0.700 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2019 | 1 | 0.700 |
Why?
|
| Humans | 38 | 2022 | 34853 | 0.690 |
Why?
|
| Female | 26 | 2020 | 19873 | 0.680 |
Why?
|
| Mycosis Fungoides | 1 | 2018 | 2 | 0.660 |
Why?
|
| Mycobacterium leprae | 2 | 2017 | 2 | 0.660 |
Why?
|
| Leukoplakia, Oral | 1 | 2018 | 11 | 0.640 |
Why?
|
| Leprosy, Lepromatous | 1 | 2017 | 1 | 0.640 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 15 | 0.630 |
Why?
|
| Staining and Labeling | 1 | 2017 | 100 | 0.610 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 6 | 0.600 |
Why?
|
| Glioma | 1 | 2017 | 76 | 0.590 |
Why?
|
| India | 8 | 2020 | 82 | 0.590 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 122 | 0.580 |
Why?
|
| Adult | 19 | 2020 | 11034 | 0.580 |
Why?
|
| Vitelline Duct | 1 | 2016 | 1 | 0.580 |
Why?
|
| Umbilicus | 1 | 2016 | 4 | 0.580 |
Why?
|
| Intestinal Fistula | 1 | 2016 | 4 | 0.580 |
Why?
|
| Ascomycota | 1 | 2016 | 15 | 0.580 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 859 | 0.570 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 151 | 0.570 |
Why?
|
| Exophiala | 1 | 2015 | 1 | 0.560 |
Why?
|
| Sigmoid Neoplasms | 1 | 2015 | 1 | 0.560 |
Why?
|
| Ovarian Cysts | 1 | 2015 | 2 | 0.550 |
Why?
|
| Dermatomycoses | 1 | 2015 | 7 | 0.550 |
Why?
|
| Myxoma | 1 | 2015 | 5 | 0.550 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 52 | 0.550 |
Why?
|
| Middle Aged | 17 | 2019 | 9642 | 0.550 |
Why?
|
| Vulvar Neoplasms | 1 | 2015 | 12 | 0.550 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 200 | 0.550 |
Why?
|
| Adenoma | 1 | 2016 | 89 | 0.520 |
Why?
|
| Gene Expression | 1 | 2018 | 639 | 0.510 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 211 | 0.460 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2017 | 11 | 0.450 |
Why?
|
| Kidney | 3 | 2019 | 322 | 0.430 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 65 | 0.400 |
Why?
|
| Male | 19 | 2019 | 18870 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 206 | 0.380 |
Why?
|
| Splenic Artery | 1 | 2009 | 2 | 0.360 |
Why?
|
| Splenic Diseases | 1 | 2009 | 2 | 0.360 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1426 | 0.360 |
Why?
|
| Necrosis | 1 | 2009 | 45 | 0.350 |
Why?
|
| Meckel Diverticulum | 1 | 2008 | 1 | 0.340 |
Why?
|
| Jejunal Diseases | 1 | 2008 | 2 | 0.340 |
Why?
|
| Choristoma | 1 | 2008 | 4 | 0.340 |
Why?
|
| Pancreas | 1 | 2008 | 32 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2006 | 133 | 0.330 |
Why?
|
| Ultrasonography | 2 | 2019 | 115 | 0.320 |
Why?
|
| Muscle Neoplasms | 1 | 2007 | 1 | 0.310 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2007 | 2 | 0.310 |
Why?
|
| Multicystic Dysplastic Kidney | 1 | 2007 | 2 | 0.300 |
Why?
|
| Treatment Outcome | 4 | 2019 | 1349 | 0.300 |
Why?
|
| Maxillary Neoplasms | 1 | 2006 | 1 | 0.300 |
Why?
|
| Odontogenic Tumors | 1 | 2006 | 1 | 0.300 |
Why?
|
| Maxilla | 1 | 2006 | 8 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 42 | 0.290 |
Why?
|
| Keratins | 2 | 2022 | 25 | 0.290 |
Why?
|
| Calcinosis | 1 | 2006 | 56 | 0.280 |
Why?
|
| Infant, Newborn | 4 | 2016 | 871 | 0.280 |
Why?
|
| Placenta Diseases | 1 | 2005 | 5 | 0.280 |
Why?
|
| Fibrosarcoma | 1 | 2005 | 7 | 0.280 |
Why?
|
| Chorionic Villi | 1 | 2005 | 4 | 0.280 |
Why?
|
| Hemangioma | 1 | 2005 | 7 | 0.280 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 32 | 0.270 |
Why?
|
| Abdominal Injuries | 1 | 2004 | 6 | 0.260 |
Why?
|
| Thoracic Injuries | 1 | 2004 | 10 | 0.260 |
Why?
|
| Wilms Tumor | 1 | 2004 | 4 | 0.260 |
Why?
|
| Child | 5 | 2019 | 2875 | 0.260 |
Why?
|
| Fibroma | 1 | 2004 | 4 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 36 | 0.250 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 203 | 0.250 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2004 | 2 | 0.250 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 132 | 0.240 |
Why?
|
| Adolescent | 7 | 2017 | 5035 | 0.240 |
Why?
|
| Pleural Neoplasms | 1 | 2004 | 51 | 0.240 |
Why?
|
| Epithelial Cells | 1 | 2006 | 366 | 0.230 |
Why?
|
| Child, Preschool | 4 | 2017 | 1318 | 0.230 |
Why?
|
| Prognosis | 3 | 2015 | 707 | 0.230 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 53 | 0.220 |
Why?
|
| Young Adult | 6 | 2019 | 4012 | 0.220 |
Why?
|
| Cotton Fiber | 1 | 2022 | 4 | 0.220 |
Why?
|
| Mucin-1 | 1 | 2022 | 8 | 0.220 |
Why?
|
| Infant | 2 | 2019 | 1014 | 0.190 |
Why?
|
| Biopsy | 2 | 2019 | 151 | 0.190 |
Why?
|
| Retrospective Studies | 3 | 2017 | 1961 | 0.190 |
Why?
|
| Preoperative Care | 1 | 2019 | 25 | 0.180 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1149 | 0.180 |
Why?
|
| Abdomen | 2 | 2017 | 12 | 0.170 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2019 | 17 | 0.170 |
Why?
|
| Adrenal Glands | 1 | 2019 | 17 | 0.170 |
Why?
|
| Hyperpigmentation | 1 | 2018 | 10 | 0.170 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 53 | 0.170 |
Why?
|
| Histocytochemistry | 2 | 2009 | 45 | 0.160 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1056 | 0.160 |
Why?
|
| Suppuration | 1 | 2017 | 3 | 0.160 |
Why?
|
| Histological Techniques | 1 | 2017 | 14 | 0.160 |
Why?
|
| Breast | 1 | 2019 | 134 | 0.160 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 555 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 3 | 2006 | 105 | 0.150 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2016 | 3 | 0.150 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 11 | 0.150 |
Why?
|
| DNA, Fungal | 1 | 2016 | 40 | 0.140 |
Why?
|
| Hand | 1 | 2016 | 23 | 0.140 |
Why?
|
| Microscopy | 1 | 2016 | 32 | 0.140 |
Why?
|
| Radiography | 1 | 2016 | 75 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 468 | 0.140 |
Why?
|
| Intestines | 1 | 2016 | 63 | 0.140 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2007 | 4 | 0.140 |
Why?
|
| Burns | 1 | 2015 | 8 | 0.140 |
Why?
|
| Cicatrix | 1 | 2015 | 17 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 455 | 0.120 |
Why?
|
| Quality of Life | 1 | 2018 | 459 | 0.120 |
Why?
|
| Aged | 6 | 2012 | 6448 | 0.120 |
Why?
|
| Macrophages | 1 | 2017 | 431 | 0.120 |
Why?
|
| Temefos | 1 | 2013 | 1 | 0.120 |
Why?
|
| Culex | 1 | 2013 | 4 | 0.120 |
Why?
|
| Insecticide Resistance | 1 | 2013 | 7 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 577 | 0.110 |
Why?
|
| Insecticides | 1 | 2013 | 47 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2006 | 528 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2012 | 15 | 0.110 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 19 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 63 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 157 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2013 | 301 | 0.090 |
Why?
|
| Metals, Rare Earth | 1 | 2009 | 3 | 0.090 |
Why?
|
| Barium | 1 | 2009 | 15 | 0.090 |
Why?
|
| Glass | 1 | 2009 | 15 | 0.090 |
Why?
|
| Aluminum | 1 | 2009 | 34 | 0.090 |
Why?
|
| Energy Transfer | 1 | 2009 | 36 | 0.090 |
Why?
|
| Hyaline Cartilage | 1 | 2009 | 1 | 0.090 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2009 | 2 | 0.090 |
Why?
|
| Phosphates | 1 | 2009 | 49 | 0.090 |
Why?
|
| Splenectomy | 1 | 2009 | 7 | 0.090 |
Why?
|
| Pregnancy | 2 | 2005 | 1503 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 89 | 0.090 |
Why?
|
| Eye | 1 | 2009 | 68 | 0.090 |
Why?
|
| Peritonitis | 1 | 2008 | 8 | 0.080 |
Why?
|
| Duodenal Ulcer | 1 | 2008 | 5 | 0.080 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 10 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2008 | 74 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 81 | 0.080 |
Why?
|
| Apoptosis | 2 | 2012 | 1317 | 0.080 |
Why?
|
| Mechlorethamine | 1 | 2007 | 1 | 0.080 |
Why?
|
| Procarbazine | 1 | 2007 | 1 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2007 | 6 | 0.080 |
Why?
|
| Vinblastine | 1 | 2007 | 9 | 0.080 |
Why?
|
| Vincristine | 1 | 2007 | 13 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 16 | 0.080 |
Why?
|
| Prednisone | 1 | 2007 | 26 | 0.080 |
Why?
|
| Bleomycin | 1 | 2007 | 18 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2007 | 20 | 0.070 |
Why?
|
| Maxillary Sinus | 1 | 2006 | 4 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2006 | 11 | 0.070 |
Why?
|
| Orbit | 1 | 2006 | 9 | 0.070 |
Why?
|
| Mesoderm | 1 | 2007 | 70 | 0.070 |
Why?
|
| Leprosy, Borderline | 1 | 2006 | 1 | 0.070 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2006 | 1 | 0.070 |
Why?
|
| Epithelium | 1 | 2007 | 74 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 60 | 0.070 |
Why?
|
| S100 Proteins | 1 | 2006 | 12 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 80 | 0.070 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2006 | 10 | 0.070 |
Why?
|
| Peripheral Nerves | 1 | 2006 | 14 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2006 | 25 | 0.070 |
Why?
|
| Genes, ras | 1 | 2006 | 22 | 0.070 |
Why?
|
| Vimentin | 1 | 2006 | 32 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 86 | 0.070 |
Why?
|
| Arm | 1 | 2005 | 25 | 0.070 |
Why?
|
| Actins | 1 | 2006 | 142 | 0.070 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 8 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2006 | 1353 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 178 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 903 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2004 | 4 | 0.070 |
Why?
|
| Wounds, Stab | 1 | 2004 | 5 | 0.070 |
Why?
|
| Multiple Trauma | 1 | 2004 | 7 | 0.070 |
Why?
|
| Genes, BRCA2 | 1 | 2004 | 6 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2004 | 13 | 0.070 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2004 | 28 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2004 | 24 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 430 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 2333 | 0.060 |
Why?
|
| Wounds, Gunshot | 1 | 2004 | 26 | 0.060 |
Why?
|
| Neoplastic Processes | 1 | 2004 | 2 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 51 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 33 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2003 | 3 | 0.060 |
Why?
|
| Lymphangioma | 1 | 2003 | 5 | 0.060 |
Why?
|
| Hamartoma | 1 | 2003 | 6 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2005 | 628 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 36 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2004 | 135 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 964 | 0.050 |
Why?
|
| Lung | 1 | 2004 | 413 | 0.050 |
Why?
|
| Dermatitis, Contact | 1 | 2018 | 2 | 0.040 |
Why?
|
| Prurigo | 1 | 2018 | 2 | 0.040 |
Why?
|
| Lichen Planus | 1 | 2018 | 5 | 0.040 |
Why?
|
| Amyloidosis | 1 | 2018 | 33 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 58 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2013 | 10 | 0.030 |
Why?
|
| Biological Assay | 1 | 2013 | 56 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 126 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 322 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 213 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 484 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 423 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 517 | 0.020 |
Why?
|
| Neodymium | 1 | 2009 | 3 | 0.020 |
Why?
|
| Erbium | 1 | 2009 | 2 | 0.020 |
Why?
|
| Ytterbium | 1 | 2009 | 2 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 22 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 35 | 0.020 |
Why?
|
| Optical Phenomena | 1 | 2009 | 21 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 490 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 18 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2009 | 16 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 48 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 27 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 727 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1007 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 859 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 196 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 878 | 0.020 |
Why?
|
| Epithelioid Cells | 1 | 2006 | 1 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2006 | 32 | 0.020 |
Why?
|
| Granuloma | 1 | 2006 | 23 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1681 | 0.020 |
Why?
|
| Pedigree | 1 | 2004 | 64 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 3414 | 0.010 |
Why?
|
| Mesentery | 1 | 2003 | 9 | 0.010 |
Why?
|
| Pelvis | 1 | 2003 | 14 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 1425 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 14307 | 0.010 |
Why?
|